Inhaled insulin was dropped by Pfizer when it withdrew Exubera from the market, and in January 2016, Sanofi withdrew the marketing agreement with MannKind for Afrezza; both removals were due to poor sales volume. Not to mention the dire contraindications, of which hypoglycemia was one (a potentially deadly low blood sugar condition that will rock your world and leave you puking your guts out and shaking, sweating profusely, and unable to walk for the hallucinogenic head spins).

The Sanofi CEO is the past CEO of Novartis

MNKD stock price has been crushed from $5 to $1.66 since they closed the deal in 2016. The CEO is a pharmacist.

Management matters...